ReviewJournal of Alzheimer's disease : JAD2023
Neuropsychiatric Symptoms and Commonly Used Biomarkers of Alzheimer's Disease: A Literature Review from a Machine Learning Perspective.
Review in Journal of Alzheimer's disease : JAD, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Frontiers and hotspots evolution in mild cognitive impairment: a bibliometric analysis of from 2013 to 2023.Frontiers in neuroscience · 2024Pooled it
- Machine Learning and Multimodal Biomarker Discovery in Alzheimer's Disease.Brain sciences · 2026Review
- RDoC-informed explainable AI as a paradigm for multilevel Alzheimer's disease diagnosis and progression prediction: a systematic review.Brain informatics · 2026Review
- Current Advancements in Untargeted Metabolomics Analysis and Testing Driven by Machine Learning: Prospects for Artificial Intelligence in Patient-Centric Healthcare Transformation.Applied biochemistry and biotechnology · 2026Review
- Predictive factors for dementia among older adults in South Korea: an interpretable machine learning analysis.Alzheimer's research & therapy · 2025Article
- From Serendipity to Precision: Integrating AI, Multi-Omics, and Human-Specific Models for Personalized Neuropsychiatric Care.Biomedicines · 2025Review
- Editorial: Recent advances in research on cognitive frailty and related conditions.Frontiers in aging neuroscience · 2025Article
- Integrating genetic and immune profiles for personalized immunotherapy in Alzheimer's disease.Frontiers in medicine · 2025Review
- Biomarkers and immunotherapy in endometrial cancer: mechanisms and clinical applications.Frontiers in immunology · 2025Review
- Advancing gastrointestinal stromal tumor management: The role of imagomics features in precision risk assessment.World journal of gastrointestinal surgery · 2024Article
- Using AI-Based Technologies to Help Nurses Detect Behavioral Disorders: Narrative Literature Review.JMIR nursing · 2024Review
- Association between Alzheimer's disease pathologic products and age and a pathologic product-based diagnostic model for Alzheimer's disease.Frontiers in aging neuroscience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
There is a growing interest in the application of machine learning (ML) in Alzheimer's disease (AD) research. However, neuropsychiatric symptoms (NPS), frequent in subjects with AD, mild cognitive impairment (MCI), and other related dementias have not been analyzed sufficiently using ML methods. To portray the landscape and potential of ML research in AD and NPS studies, we present a comprehensive literature review of existing ML approaches and commonly studied AD biomarkers. We conducted PubMed searches with keywords related to NPS, AD biomarkers, machine learning, and cognition. We included a total of 38 articles in this review after excluding some irrelevant studies from the search results and including 6 articles based on a snowball search from the bibliography of the relevant studies. We found a limited number of studies focused on NPS with or without AD biomarkers. In contrast, multiple statistical machine learning and deep learning methods have been used to build predictive diagnostic models using commonly known AD biomarkers. These mainly included multiple imaging biomarkers, cognitive scores, and various omics biomarkers. Deep learning approaches that combine these biomarkers or multi-modality datasets typically outperform single-modality datasets. We conclude ML may be leveraged to untangle the complex relationships of NPS and AD biomarkers with cognition. This may potentially help to predict the progression of MCI or dementia and develop more targeted early intervention approaches based on NPS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.